Journal
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
Volume 8, Issue 8, Pages 875-885Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474124.2014.922870
Keywords
colorectal cancer; gastric cancer; gastrointestinal tumors; hepatocellular carcinoma; neuroendocrine tumors; targeted therapy
Categories
Ask authors/readers for more resources
Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available